|
|
News Breaks | | | | December 9, 2012 | | 16:40 EDT |  | TKPYY | Millennium and Takeda report data from Phase I trial of ADCETRIS
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited announced results from two arms of a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma, MTCL, patients, including patients with systemic anaplastic large cell lymphoma, sALCL. These data were presented at the 54th American Society of Hematology, ASH, Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate, ADC, directed to CD30. ADCETRIS is not approved for use in the front-line treatment of MTCL. | |
|
News For TKPYY From The Last 14 Days Check below for free stories on TKPYY the last two weeks. |
|
|
| May 7, 2013 | | 19:03 EDT | | TKPYY | Takeda to buy Inviragen
 Subscribe for More Information | | | 17:57 EDT | | TKPYY | Sucampo expects to recognize $10M milestone payment for Amitiza in Q2
The payment is from Takeda Pharmaceutical (TKPYY). | |
|
|
|
|
|
|
